Patents by Inventor Hiroshi Nakatake

Hiroshi Nakatake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8427225
    Abstract: To obtain a gate driving circuit in which rising of a constant current of a constant current circuit is fast and power saving is achieved, the gate driving circuit includes: a constant current driving circuit (28) for supplying a constant current; a gate terminal of a power semiconductor element (1), which is connected to an output terminal of the constant current driving circuit; a comparator (22) for comparing a voltage at the gate terminal with a predetermined voltage value and outputting a signal indicating that the voltage is higher than the predetermined voltage value; and a driving control section (20) for increasing a current from the constant current driving circuit in response to a signal for turning on the power semiconductor element, and reducing the current from the constant current driving circuit in response to the signal from the comparator.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: April 23, 2013
    Assignee: Mitsubishi Electric Corporation
    Inventors: Hiroshi Nakatake, Masaru Fuku, Tatsuya Okuda, Yoshikazu Tsunoda
  • Patent number: 8293874
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 23, 2012
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Publication number: 20120231523
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 13, 2012
    Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST
    Inventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Publication number: 20120153998
    Abstract: A gate drive circuit capable of turning on a semiconductor switching element at high speed, which includes: a buffer circuit including a turn-on-drive switching element and a turn-off-drive switching element that are complementarily turned on and off, for driving the semiconductor switching element; a first DC voltage supply including a positive electrode connected to the source or emitter of the turn-on-drive switching element and a negative electrode connected to a reference potential; and a second DC voltage supply including a positive electrode connected to the source or emitter of the turn-off-drive switching element and a negative electrode connected to the reference potential.
    Type: Application
    Filed: September 2, 2010
    Publication date: June 21, 2012
    Applicant: MITSUBISHI ELECTRIC CORPORATION
    Inventors: Tatsuya Kitamura, Hiroshi Nakatake, Yasushi Nakayama
  • Publication number: 20120126791
    Abstract: An output of a current sensing cell is connected to an inverting input terminal of an operational amplifier, and a non-inverting input terminal of the operational amplifier is connected to the source, of the main cell, to which a source-bias voltage is applied; a current/voltage conversion circuit configured with the operational amplifier and a sensing resistor converts an output current of the current sensing cell into a sensing voltage; there are provided a first error detection circuit that compares the sensing voltage with a first reference voltage and outputs an error signal and a second error detection circuit that compares a voltage at the inverting input terminal of the operational amplifier with a second reference voltage set to be higher than the source-bias voltage and outputs an error signal.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 24, 2012
    Applicant: Mitsubishi Electric Corporation
    Inventor: Hiroshi Nakatake
  • Publication number: 20120114057
    Abstract: A wireless communication device or an access point includes: a main unit; an external antenna unit; a throughput check module; and a notification controller, a notice applying circuit and a notice generating circuit. The main unit is for including a communication control circuit. The external antenna unit is for including an antenna and is electrically connected with the main unit via a cable. The throughput check module is for checking throughput of communication with another wireless communication device or a station. The notification controller, the notice applying circuit and the notice generating circuit are for notifying a user of system information based on check result by the throughput check module, by using the external antenna unit. This configuration improves the work efficiency of antenna adjustment at the wireless communication device using the external antenna unit.
    Type: Application
    Filed: November 3, 2011
    Publication date: May 10, 2012
    Applicant: Buffalo Inc.
    Inventors: Hiroshi NAKATAKE, Hiroaki Goto, Nagahiro Matsuura
  • Patent number: 8173777
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: May 8, 2012
    Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Publication number: 20120066525
    Abstract: The rotating speed of a cooling fan is controlled in accordance with the number of devices connected to ports of a packet transmitting/receiving unit and a connection speed with that device. When the number of ports establishing a link at a speed of 1 Gbps is zero, the voltage value of power output from a power source block to the cooling fan is 0 V and the cooling fan is deactivated. When the number of ports establishing a link at a speed of 1 Gbps is one or two, the voltage value is 8 V and the cooling fan rotates in a slow mode. Furthermore, when the number of ports establishing a link at a speed of 1 Gbps is three or four, the voltage value is 12 V and the cooling fan rotates in a fast mode.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 15, 2012
    Applicant: Buffalo Inc.
    Inventors: Nobuhiro TAMURA, Hiroshi NAKATAKE
  • Publication number: 20120039863
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Application
    Filed: September 16, 2011
    Publication date: February 16, 2012
    Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST
    Inventors: Kenji SOEJIMA, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Publication number: 20120013371
    Abstract: A gate driving circuit for driving a voltage-driven switching device is provided with a current limiting circuit for limiting a gate current ig that flows into a gate terminal through a gate resistor at turn-on to a current limit value IL which defines an upper limit value. The current limit value IL is set at a value which is larger than a gate current value I2 at turn-on of the switching device during a period when the Miller effect occurs but is smaller than a gate current value I1 at a point in time when a main current begins to flow at turn-on in a case where the gate current ig is not limited by the current limiting circuit. This arrangement makes a variation in a collector current of the switching device moderate at turn-on thereof when the collector current begins to flow, thereby reducing high-frequency noise.
    Type: Application
    Filed: May 7, 2010
    Publication date: January 19, 2012
    Applicant: MITSUBISHI ELECTRIC CORPORATION
    Inventors: Hiroshi Nakatake, Shinichi Kinouchi, Tatsuya Kitamura
  • Publication number: 20110262998
    Abstract: A process for preparing an inclusion body-forming protein is provided.
    Type: Application
    Filed: October 21, 2009
    Publication date: October 27, 2011
    Applicants: TEIJIN PHARMA LIMITED, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Hiroshi Nakatake, Akihiro Meta, Kiyotaka Suenaga, Masaki Hirashima, Hiroaki Maeda
  • Patent number: 7948277
    Abstract: A drive circuit wherein any abnormality of a semiconductor element is prevented from being erroneously sensed in a case where a gate “ON” command has entered in a state in which a gate voltage of the semiconductor element has not lowered fully. A detection process for a controlled variable of the semiconductor element is permitted only within a period which corresponds to a controlled variable of the semiconductor element at the time when an “ON” signal has been inputted to a control circuit, and a detected controlled variable which is detected within the period and a comparison controlled variable which is set in correspondence with the controlled variable are compared so as to output an abnormality signal, whereby the semiconductor element is turn-off at a speed lower than in normal turn-off.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: May 24, 2011
    Assignee: Mitsubishi Electric Corporation
    Inventors: Hiroshi Nakatake, Satoshi Ishibashi, Shinsuke Idenoue, Takeshi Oi, Shinichi Kinouchi, Takeshi Horiguchi
  • Publication number: 20100285568
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Application
    Filed: October 8, 2008
    Publication date: November 11, 2010
    Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST
    Inventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Publication number: 20100231269
    Abstract: A drive circuit wherein any abnormality of a semiconductor element is prevented from being erroneously sensed in a case where a gate “ON” command has entered in a state in which a gate voltage of the semiconductor element has not lowered fully. A detection process for a controlled variable of the semiconductor element is permitted only within a period which corresponds to a controlled variable of the semiconductor element at the time when an “ON” signal has been inputted to a control circuit, and a detected controlled variable which is detected within the period and a comparison controlled variable which is set in correspondence with the controlled variable are compared so as to output an abnormality signal, whereby the semiconductor element is turn-off at a speed lower than in normal turn-off.
    Type: Application
    Filed: April 4, 2007
    Publication date: September 16, 2010
    Applicant: MITSUBISHI ELECTRIC CORPORATION
    Inventors: Hiroshi Nakatake, Satoshi Ishibashi, Shinsuke Idenoue, Takeshi Oi, Shinichi Kinouchi, Takeshi Horiguchi
  • Publication number: 20100213989
    Abstract: To obtain a gate driving circuit in which rising of a constant current of a constant current circuit is fast and power saving is achieved, the gate driving circuit includes: a constant current driving circuit (28) for supplying a constant current; a gate terminal of a power semiconductor element (1), which is connected to an output terminal of the constant current driving circuit; a comparator (22) for comparing a voltage at the gate terminal with a predetermined voltage value and outputting a signal indicating that the voltage is higher than the predetermined voltage value; and a driving control section (20) for increasing a current from the constant current driving circuit in response to a signal for turning on the power semiconductor element, and reducing the current from the constant current driving circuit in response to the signal from the comparator.
    Type: Application
    Filed: September 3, 2008
    Publication date: August 26, 2010
    Applicant: Mitsubishi Electric Corporation
    Inventors: Hiroshi Nakatake, Masaru Fuku, Tatsuya Okuda, Yoshikazu Tsunoda
  • Patent number: 7635577
    Abstract: A genetic recombinant human thrombin is provided. Human thrombin is efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transfectant animal cell transfected with an expression vector in which a gene encoding human prethrombin is incorporated to the downstream of a promoter so as to produce and accumulate prethrombin in culture supernatant and recovering the produced human prethrombin; (2) treating a solution containing human prethrombin recovered in step (1) with ecarin so as to convert human prethrombin into human thrombin; and (3) purifying the solution obtained after the above activation process to obtain purified human thrombin. The present invention allows for provision of human thrombin in a large scale in a safe and economical manner due to exclusion of blood-derived components.
    Type: Grant
    Filed: July 4, 2002
    Date of Patent: December 22, 2009
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiroshi Yonemura, Tajayuki Imamura, Hiroshi Nakatake, Kenji Soejima, Chikateru Nozaki
  • Publication number: 20090137001
    Abstract: The present invention provides for a process for preparing a recombinant human thrombin. A process for preparing a recombinant human thrombin which comprises: (1) obtaining a transfectant cell producing a human prothrombin by introducing an expression vector, wherein a gene fragment coding for a human prothrombin gene is incorporated, into an animal cell; (2) purifying a human prothrombin from the culture of the transfectant cell above by an anion exchanger; (3) converting the purified human prothrombin into a human thrombin by subjecting said human prothrombin to the action of ecarin; and (4) purifying the human thrombin from the solution after treatment with ecarin by an affinity method using benzamidine and a cation exchanger, and human thrombin obtained by said process, and a CHO cell that produces human prothrombin.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 28, 2009
    Inventors: Tatsufumi Onchi, Yo Nakahara, Takayuki Imamura, Toshinobu Nouchi, Hiroshi Nakatake
  • Publication number: 20080153132
    Abstract: A recombinant ecarin protein that specifically activates prothrombin, said protein being efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transformant microorganism or animal cell transformed with an expression vector in which a gene encoding ecarin is incorporated to the downstream of a promoter so as to produce and accumulate ecarin in culture supernatant or within said transformant and recovering the produced ecarin; and (2) purifying a solution containing the recovered ecarin to obtain purified ecarin. The present invention allows for production of recombinant ecarin on an industrial scale.
    Type: Application
    Filed: December 5, 2007
    Publication date: June 26, 2008
    Applicant: JURIDICAL FOUNDATION THE CHEMO-SERO- THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Hiroshi YONEMURA, Takayuki IMAMURA, Hiroshi NAKATAKE, Kenji SOEJIMA, Chikateru NOZAKI
  • Publication number: 20050164365
    Abstract: A recombinant ecarin protein that specifically activates prothrombin, said protein being efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transformant microorganism or animal cell transformed with an expression vector in which a gene encoding ecarin is incorporated to the downstream of a promoter so as to produce and accumulate ecarin in culture supernatant or within said transformant and recovering the produced ecarin; and (2) purifying a solution containing the recovered ecarin to obtain purified ecarin. The present invention allows for production of recombinant ecarin on an industrial scale.
    Type: Application
    Filed: July 4, 2002
    Publication date: July 28, 2005
    Applicant: Juridical Foundation The Chemosero-Therapeutic Research Institute
    Inventors: Hiroshi Yonemura, Takayuki Imamura, Hiroshi Nakatake, Kenji Soejima, Chikateru Nozaki
  • Publication number: 20040197858
    Abstract: A genetic recombinant human thrombin is provided. Human thrombin is efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transfectant animal cell transfected with an expression vector in which a gene encoding human prethrombin is incorporated to the downstream of a promoter so as to produce and accumulate prethrombin in culture supernatant and recovering the produced human prethrombin; (2) treating a solution containing human prethrombin recovered in step (1) with ecarin so as to convert human prethrombin into human thrombin; and (3) purifying the solution obtained after the above activation process to obtain purified human thrombin. The present invention allows for provision of human thrombin in a large scale in a safe and economical manner due to exclusion of blood-derived components.
    Type: Application
    Filed: January 6, 2004
    Publication date: October 7, 2004
    Inventors: Hiroshi Yonemura, Takayuki Imamura, Hiroshi Nakatake, Kenji Soejima, Chikateru Nozaki